论文部分内容阅读
目的：研究３２磷－玻璃微球（３２Ｐ－ＧＭＳ）区域给药的药代动力学特点，探讨靶组织内辐照量和吸收剂量的估算方法。方法：模拟人类对７只家猪经肝动脉灌注给药或间质注射，对２０只人肝癌移植瘤裸鼠瘤体内注射，动态观测３２Ｐ－ＧＭＳ的分布与放射性计数率的衰减。结果：３２Ｐ－ＧＭＳ通过肝动脉给药，可有效栓塞至肝窦前小动脉，通过瘤体内注射可滞留在靶组织内不被排泄，给药第１４天的衰减分数为０．４８，其有效半减期与３２Ｐ物理半衰期值接近。经计算，３２Ｐ－ＧＭＳ放射性活度为３７ＭＢｑ时，在１ｋｇ肝组织内完全衰变，组织所接受的宏观平均吸收剂量是７３２ｃＧｙ。结论：本研究为３２Ｐ－ＧＭＳ对肝癌治疗的实验研究和临床应用提供了科学的剂量学依据。３２Ｐ－ＧＭＳ区域给药的稳定性使它逐步成为一种安全有效的内放射治疗肝癌的重要手段。
OBJECTIVE: To study the pharmacokinetics of 32-phospho-glass microspheres (32P-GMS) administered in the region and to investigate the methods for estimating the amount of radiation and absorbed dose in the target tissue. METHODS: Human hepatic arterial infusion or interstitial injection was performed on 7 domestic human swine. Twenty human hepatoma transplanted tumors were injected intratumorally in nude mice. The distribution of 32P-GMS and attenuation of radioactivity counting rate were observed dynamically. Results: 32P-GMS can be effectively embolized into the hepatic sinusoidal arteries by intrahepatic arterial injection. It can be retained in the target tissue without being excreted by intratumoral injection. The attenuation score on the 14th day of administration is 0.48. The half-life period is similar to the 32P physical half-life value. It was calculated that when the 32P-GMS activity was 37 MBq, it completely decayed in 1 kg of liver tissue, and the macroscopic average absorbed dose received by the tissue was 732 cGy. Conclusion: This study provides a scientific dosimetric basis for the experimental study and clinical application of 32P-GMS in the treatment of liver cancer. The stability of 32P-GMS regional administration makes it gradually become a safe and effective internal radiation therapy for liver cancer.